1. Home
  2. CYTK vs RUN Comparison

CYTK vs RUN Comparison

Compare CYTK & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • RUN
  • Stock Information
  • Founded
  • CYTK 1997
  • RUN 2007
  • Country
  • CYTK United States
  • RUN United States
  • Employees
  • CYTK N/A
  • RUN N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • RUN Industrial Machinery/Components
  • Sector
  • CYTK Health Care
  • RUN Miscellaneous
  • Exchange
  • CYTK Nasdaq
  • RUN Nasdaq
  • Market Cap
  • CYTK 4.6B
  • RUN 3.7B
  • IPO Year
  • CYTK 2004
  • RUN 2015
  • Fundamental
  • Price
  • CYTK $60.16
  • RUN $16.79
  • Analyst Decision
  • CYTK Strong Buy
  • RUN Buy
  • Analyst Count
  • CYTK 15
  • RUN 20
  • Target Price
  • CYTK $76.73
  • RUN $20.18
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • RUN 7.8M
  • Earning Date
  • CYTK 11-05-2025
  • RUN 11-06-2025
  • Dividend Yield
  • CYTK N/A
  • RUN N/A
  • EPS Growth
  • CYTK N/A
  • RUN N/A
  • EPS
  • CYTK N/A
  • RUN N/A
  • Revenue
  • CYTK $87,211,000.00
  • RUN $2,316,656,000.00
  • Revenue This Year
  • CYTK $363.61
  • RUN $11.35
  • Revenue Next Year
  • CYTK $64.33
  • RUN $9.26
  • P/E Ratio
  • CYTK N/A
  • RUN N/A
  • Revenue Growth
  • CYTK 2609.26
  • RUN 13.79
  • 52 Week Low
  • CYTK $29.31
  • RUN $5.38
  • 52 Week High
  • CYTK $64.13
  • RUN $22.44
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 55.21
  • RUN 38.89
  • Support Level
  • CYTK $58.05
  • RUN $18.72
  • Resistance Level
  • CYTK $61.29
  • RUN $21.34
  • Average True Range (ATR)
  • CYTK 2.60
  • RUN 1.28
  • MACD
  • CYTK -0.48
  • RUN -0.36
  • Stochastic Oscillator
  • CYTK 57.88
  • RUN 10.37

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

Share on Social Networks: